Subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings (00874) received Macao pharmaceutical registration certificate.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Guanghua Pharmaceutical Co., Ltd. ("Guanghua Pharmaceutical") recently received the "Chinese Medicine Registration Certificate" issued by the Macao Special Administrative Region Government Drug Supervision Administration. Guanghua Pharmaceutical submitted applications for the registration of Xiao Chaihu Granules (sugar-free) and Xiao Chaihu Granules to the Macao Special Administrative Region Government Drug Supervision Administration on September 28, 2023, and they were accepted on October 20, 2023. Xiao Chaihu Granules are used for exterior conditions, dispelling heat, regulating the liver, and soothing the stomach. They are used for exterior pathogens invading the Shaoyang stage, with symptoms such as alternating fever and chills, fullness and discomfort in the chest and rib cage, loss of appetite, restlessness, vomiting, bitterness in the mouth, and dry throat. According to data from Mi Nei, in 2023, the sales of Xiao Chaihu Granules in public hospitals and urban retail pharmacies in China were RMB 354.35 million and RMB 1.1739 billion, respectively. In 2023, the sales revenue of Guanghua Pharmaceutical's Xiao Chaihu Granules (sugar-free) and Xiao Chaihu Granules were RMB 95.1981 million and RMB 429.2148 million, respectively. As of the date of this announcement, Guanghua Pharmaceutical has invested approximately RMB 9.1971 million (unaudited) in the above-mentioned drug development projects. After obtaining the "Chinese Medicine Registration Certificate" issued by the Macao Special Administrative Region Government Drug Supervision Administration, the above-mentioned drugs will be authorized for sale in the Macao area by De Sheng Tang Pharmaceuticals Import and Wholesale Company, helping Guanghua Pharmaceutical expand its overseas market business and improve the competitiveness of its products in the market. The acquisition of the "Chinese Medicine Registration Certificate" for the above-mentioned drugs will not have a significant impact on the company's current performance.